Locking the 150-Cavity Open: In Silico Design and Verification of Influenza Neuraminidase Inhibitors

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Han, Nanyu ^a   Mu, Yuguang ^a  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

SIALIDASE INHIBITOR; VIRUS SIALIDASE; ZANAMIVIR;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVE SITE; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS;

DRUG DESIGN; ENZYME INHIBITORS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; MOLECULAR DOCKING SIMULATION; NEURAMINIDASE; ZANAMIVIR;

EID: 84883174494     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073344     Document Type: Article

References (50)

1. Fauci AS, (2006) Pandemic influenza threat and preparedness. Emerg Infect Dis 12: 73-77. PubMed: 16494721.
2. Neumann G, Noda T, Kawaoka Y, (2009) Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459: 931-939. doi:10.1038/nature08157. PubMed: 19525932.
3. Peiris JSM, de Jong MD, Guan Y, (2007) Avian influenza virus (H5N1): a threat to human health. Clin Microbiol Rev 20: 243-267. doi:10.1128/CMR.00037-06. PubMed: 17428885.
4. Nistal-Villán E, García-Sastre A, (2009) New prospects for the rational design of antivirals. Nat Med 15: 1253-1254. doi:10.1038/nm1109-1253. PubMed: 19893557.
5. Das K, Aramini JM, Ma LC, Krug RM, Arnold E, (2010) Structures of influenza A proteins and insights into antiviral drug targets. Nat Struct Mol Biol 17: 530-538. doi:10.1038/nsmb.1779. PubMed: 20383144.
6. Schnell JR, Chou JJ, (2008) Structure and mechanism of the M2 proton channel of influenza A virus. Nature 451: 591-595. doi:10.1038/nature06531. PubMed: 18235503.
7. Moscona A, (2005) Drug therapy- Neuraminidase inhibitors for influenza. N Engl J Med 353: 1363-1373. doi:10.1056/NEJMra050740. PubMed: 16192481.
8. Pielak RM, Schnell JR, Chou JJ, (2009) Mechanism of drug inhibition and drug resistance of influenza A M2 channel. Proc Natl Acad Sci U S A 106: 7379-7384. doi:10.1073/pnas.0902548106. PubMed: 19383794.
9. Hayden FG, (2006) Antiviral resistance in influenza viruses- Implications for management and pandemic response. N Engl J Med 354: 785-788. doi:10.1056/NEJMp068030. PubMed: 16495389.
10. Babu YS, Chand P, Bantia S, Kotian P, Dehghani A, et al. (2000) BCX-1812 (RWJ-270201): Discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem 43: 3482-3486. doi:10.1021/jm0002679. PubMed: 11000002.
11. Kim CU, Lew W, Williams MA, Liu H, Zhang L, et al. (1997) Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 119: 681-690. doi:10.1021/ja963036t. PubMed: 16526129.
12. von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, et al. (1993) Rational Design of Potent Sialidase-Based Inhibitors of Influenza-Virus Replication. Nature 363: 418-423. doi:10.1038/363418a0. PubMed: 8502295.
13. Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, et al. (2009) CS-8958, a Prodrug of the New Neuraminidase Inhibitor R-125489, Shows Long-Acting Anti-Influenza Virus Activity. Antimicrob Agents Chemother 53: 186-192. doi:10.1128/AAC.00333-08. PubMed: 18955520.
14. Thompson JD, Higgins DG, Gibson TJ, (1994) Improved Sensitivity of Profile Searches through the Use of Sequence Weights and Gap Excision. Comput Appl Biosci 10: 19-29. PubMed: 8193951.
15. von Itzstein M, (2007) The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov 6: 967-974. doi:10.1038/nrd2400. PubMed: 18049471.
16. Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP, et al. (2006) The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443: 45-49. doi:10.1038/nature05114. PubMed: 16915235.
17. Cheng LS, Amaro RE, Xu D, Li WW, Arzberger PW, et al. (2008) Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase. J Med Chem 51: 3878-3894. doi:10.1021/jm8001197. PubMed: 18558668.
18. Landon MR, Amaro RE, Baron R, Ngan CH, Ozonoff D, et al. (2008) Novel druggable hot spots in avian influenza neuraminidase H5N1 revealed by computational solvent mapping of a reduced and representative receptor ensemble. Chem Biol Drugs Des 71: 106-116. doi:10.1111/j.1747-0285.2007.00614.x.
19. Amaro RE, Cheng XL, Ivanov I, Xu D, McCammon JA, (2009) Characterizing Loop Dynamics and Ligand Recognition in Human- and Avian-Type Influenza Neuraminidases via Generalized Born Molecular Dynamics and End-Point Free Energy Calculations. J Am Chem Soc 131: 4702-4709. doi:10.1021/ja8085643. PubMed: 19296611.
20. Amaro RE, Minh DDL, Cheng LS, Lindstrom WM, Olson AJ, et al. (2007) Remarkable loop flexibility in avian influenza N1 and its implications for antiviral drug design. J Am Chem Soc 129: 7764-7765. doi:10.1021/ja0723535. PubMed: 17539643.
21. Wang MY, Qi JX, Liu Y, Vavricka CJ, Wu Y, et al. (2011) Influenza A Virus N5 Neuraminidase Has an Extended 150-Cavity. J Virol 85: 8431-8435. doi:10.1128/JVI.00638-11. PubMed: 21653672.
22. Amaro RE, Swift RV, Votapka L, Li WW, Walker RC, et al. (2011) Mechanism of 150-cavity formation in influenza neuraminidase. Nat Commun 2: 388. doi:10.1038/ncomms1390. PubMed: 21750542.
23. Han NY, Mu YG, (2013) Plasticity of 150-Loop in Influenza Neuraminidase Explored by Hamiltonian Replica Exchange Molecular Dynamics Simulations. PLOS ONE 8: e60995. doi:10.1371/journal.pone.0060995. PubMed: 23593372.
24. Rudrawar S, Dyason JC, Rameix-Welti MA, Rose FJ, Kerry PS, et al. (2010) Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase. Nat Commun 1: 113. doi:10.1038/ncomms1114. PubMed: 21081911.
25. Wen WH, Wang SY, Tsai KC, Cheng YSE, Yang AS, et al. (2010) Analogs of zanamivir with modified C4-substituents as the inhibitors against the group-1 neuraminidases of influenza viruses. Bioorg Med Chem 18: 4074-4084. doi:10.1016/j.bmc.2010.04.010. PubMed: 20452227.
26. Mohan S, McAtamney S, Haselhorst T, von Itzstein M, Pinto BM, (2010) Carbocycles Related to Oseltamivir as Influenza Virus Group-1-Specific Neuraminidase Inhibitors. Binding to N1 Enzymes in the Context of Virus-like Particles. J Med Chem 53: 7377-7391. doi:10.1021/jm100822f. PubMed: 20873795.
27. Wang SQ, Cheng XC, Dong WL, Wang RL, Chou KC, (2010) Three new powerful oseltamivir derivatives for inhibiting the neuraminidase of influenza virus. Biochem Biophys Res Commun 401: 188-191. doi:10.1016/j.bbrc.2010.09.020. PubMed: 20849817.
28. Li Q, Qi JX, Zhang W, Vavricka CJ, Shi Y, et al. (2010) The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site. Nat Struct Mol Biol 17: 1266-1268. doi:10.1038/nsmb.1909. PubMed: 20852645.
29. van der Vries E, Collins PJ, Vachieri SG, Xiong XL, Liu JF, et al. (2012) H1N1 2009 Pandemic Influenza Virus: Resistance of the I223R Neuraminidase Mutant Explained by Kinetic and Structural Analysis. PLOS Pathog 8: e1002914. PubMed: 23028314.
30. Grienke U, Schmidtke M, Kirchmair J, Pfarr K, Wutzler P, et al. (2010) Antiviral Potential and Molecular Insight into Neuraminidase Inhibiting Diarylheptanoids from Alpinia katsumadai. J Med Chem 53: 778-786. doi:10.1021/jm901440f. PubMed: 20014777.
31. (2011) Glide. version 5.7. New York, Schrödinger, LLC.
32. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, et al. (2006) Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49: 6177-6196. doi:10.1021/jm051256o. PubMed: 17034125.
33. Wang RX, Gao Y, Lai LH, (2000) LigBuilder: A multi-purpose program for structure-based drug design. J Mol Model 6: 498-516. doi:10.1007/s0089400060498.
34. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, et al. (2009) Gaussian 09. Wallingford CT: Gaussian, Inc.
35. Dupradeau FY, Pigache A, Zaffran T, Savineau C, Lelong R, et al. (2010) The R.ED. tools: advances in RESP and ESP charge derivation and force field library building. Phys Chem Chem Phys 12: 7821-7839.
36. Wang JM, Wang W, Kollman PA, Case DA, (2006) Automatic atom type and bond type perception in molecular mechanical calculations. J Mol Graph Modell 25: 247-260. doi:10.1016/j.jmgm.2005.12.005. PubMed: 16458552.
37. Case DA, Cheatham TE, Darden T, Gohlke H, Luo R, et al. (2005) The Amber biomolecular simulation programs. J Comput Chem 26: 1668-1688. doi:10.1002/jcc.20290. PubMed: 16200636.
38. Arnold K, Bordoli L, Kopp J, Schwede T, (2006) The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22: 195-201. doi:10.1093/bioinformatics/bti770. PubMed: 16301204.
39. The PyMOL Molecular Graphics System. Version 1.5.0.4 ed: Schrödinger, LLC.
40. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML, (1983) Comparison of Simple Potential Functions for Simulating Liquid Water. J Chem Phys 79: 926-935. doi:10.1063/1.445869.
41. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, et al. (2004) UCSF chimera- A visualization system for exploratory research and analysis. J Comput Chem 25: 1605-1612. doi:10.1002/jcc.20084. PubMed: 15264254.
42. Hess B, Kutzner C, van der Spoel D, Lindahl E, (2008) GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput 4: 435-447. doi:10.1021/ct700301q.
43. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, et al. (2006) Comparison of multiple amber force fields and development of improved protein backbone parameters. Proteins Struct Funct Bioinformatics 65: 712-725. doi:10.1002/prot.21123. PubMed: 16981200.
44. Hess B, Bekker H, Berendsen HJC, Fraaije JGEM, (1997) LINCS: A linear constraint solver for molecular simulations. J Comput Chem 18: 1463-1472. doi:10.1002/(SICI)1096-987X(199709)18:12.
45. Darden T, York D, Pedersen L, (1993) Particle Mesh Ewald- an N Log(N) Method for Ewald Sums in Large Systems. J Chem Phys 98: 10089-10092. doi:10.1063/1.464397.
46. Durrant JD, de Oliveira CAF, McCammon JA, (2011) POVME: An algorithm for measuring binding-pocket volumes. J Mol Graph Modell 29: 773-776. doi:10.1016/j.jmgm.2010.10.007. PubMed: 21147010.
47. Stacklies W, Seifert C, Graeter F, (2011) Implementation of force distribution analysis for molecular dynamics simulations. BMC Bioinformatics 12: 101. doi:10.1186/1471-2105-12-101. PubMed: 21501475.
48. Chachra R, Rizzo RC, (2008) Origins of resistance conferred by the R292K neuraminidase mutation via molecular dynamics and free energy calculations. J Chem Theory Comput 4: 1526-1540. doi:10.1021/ct800068v.
49. Duan S, Boltz DA, Li J, Oshansky CM, Marjuki H, et al. (2011) Novel Genotyping and Quantitative Analysis of Neuraminidase Inhibitor Resistance-Associated Mutations in Influenza A Viruses by Single-Nucleotide Polymorphism Analysis. Antimicrob Agents Chemother 55: 4718-4727. doi:10.1128/AAC.00316-11. PubMed: 21730113.
50. Han NY, Liu XW, Mu YG, (2012) Exploring the Mechanism of Zanamivir Resistance in a Neuraminidase Mutant: A Molecular Dynamics Study. PLOS ONE 7: e44057. doi:10.1371/journal.pone.0044057. PubMed: 22970161.